EUCTR2018-001069-18-CZ进行中（未招募）1 期
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- •- Histologically- or cytologically-confirmed diagnosis of unresectable, locally advanced, or metastatic gastric cancer or GEJ adenocarcinoma
- •- No prior treatment with systemic treatment (including HER 2 inhibitors) given as primary therapy for unresectable, locally advanced, or metastatic GC or GEJ adenocarcinoma
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 294
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 126
排除标准
- •- Participants with HER2 positive status
- •- Participants with known untreated central nervous system (CNS)
- •- Uncontrolled or significant cardiovascular disease
研究者
相似试验
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations withChemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ)CancersEUCTR2018-001069-18-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO420
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations with Chemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ) CancersGastric or Gastroesophageal Junction AdenocarcinomaMedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001069-18-ATBristol-Myers Squibb International Corporation420
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations with Chemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ) CancersGastric or Gastroesophageal Junction AdenocarcinomaMedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001069-18-NOBristol-Myers Squibb International Corporation420
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations with Chemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ) CancersEUCTR2018-001069-18-DEBristol-Myers Squibb International Corporation420
进行中（未招募）
1 期
An Investigational Study of Immunotherapy Combinations with Chemotherapy in Patients with Gastric or Gastroesophageal Junction (GEJ) CancersGastric or Gastroesophageal Junction AdenocarcinomaMedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001069-18-BEBristol-Myers Squibb International Corporation420